Researchers Release Chemo-Immunotherapy Treatment Outcomes Results in Patients with KRAS-Mutant NSCLC Subtypes

Web Exclusives —July 28, 2021

Categories:

Lung Cancer

Approximately 235,000 individuals in the United States are diagnosed each year with lung cancer.1 Non–small-cell lung cancer (NSCLC) accounts for approximately 84% of these lung cancer cases. If diagnosed in the early stages, NSCLC survival rates after surgical resection are relatively high, but the majority of cases are diagnosed at advanced stages when there is only a 1-year survival rate of 10%.2 Lung adenocarcinoma, the most common type of lung cancer, represents 40% of all lung cancers.3 It is the most common subtype diagnosed in nonsmokers and evolves from the mucosal glands in the lungs.3

Cytotoxic chemotherapy has historically been the only treatment choice for patients with NSCLC, but targeted therapy against gene mutations has been introduced in recent years.4 Targeted therapy has been found to be more effective than chemotherapy and has less toxicity.4 One target for mutation is the Kirsten rat sarcoma (KRAS) mutation, an oncogenic driver in advanced NSCLC.4 The KRAS mutation predominantly occurs in lung adenocarcinoma and is a RAS/MAPK signaling cascade mediator that leads to unregulated cell growth and disease progression.5 There is great diversity among the KRAS-mutant subtypes, with KRASG12C being the most common subtype.4 These mutations occur in up to 30% of global NSCLC cases and are associated with poor patient outcomes.4,6

A study was recently released at the virtual 2021 American Society of Clinical Oncology annual meeting on the chemo-immunotherapy outcomes of patients with the KRASG12C mutation compared with other molecular KRAS-mutant NSCLC subtypes. The investigators identified 137 patients with advanced/metastatic KRAS-mutant lung cancers treated with chemo-immunotherapy regimens as first-line therapy.6 These patients were divided into KRASG12C mutation and non-G12C mutation groups. Progression-free survival (PFS) and overall survival (OS) were calculated and compared between the groups.6 KRASG12C mutations occurred in 62 patients (45%) while 55% harbored non-G12C mutations.6 In 40% of the patients with KRASG12C mutation, a concurrent STK11 mutation was identified, and KEAP1 mutations were found in 32% of the patients.6

The median OS was 21 months for KRASG12C and 14 months for patients with non-KRASG12C mutations.6 Overall, the chemo-immunotherapy response rate for patients with KRASG12C was 40% and 31% in non-KRASG12C subtypes.6 PFS was 7.3 months for KRASG12C and 6.1 months for non-KRASG12C subtypes.6 Co-mutations with STK11 and/or KEAP1 in patients with KRASG12C had an association with shorter PFS (15.8 months vs 5.1 months).6

This study demonstrated that chemo-immunotherapy treatment outcomes are similar between KRASG12C mutations and patients with non-KRASG12C subtypes and poor with concurrent STK11 and/or KEAP1 mutations.

References

  1. American Cancer Society. Key Statistics for Lung Cancer. Revised January 12, 2021. www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed June 26, 2021.
  2. Román M, Baraibar I, López I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17:33.
  3. Myers DJ, Wallen JM. Lung adenocarcinoma. National Center for Biotechnology Information StatPearls. Updated March 24, 2021. www.ncbi.nlm.nih.gov/books/NBK519578. Accessed July 12, 2021.
  4. Lei L, Wang WX, Yu ZY, et al. A real-world study in advanced non-small cell lung cancer with KRAS mutations. Transl Oncol. 2020;13:329-335.
  5. Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53-64.
  6. Arbour KC, Ricciuti B, Rizvi H, et al. Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. J Clin Oncol. 2021;39(suppl 15):9088.
Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country